MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -199.48M |
| Shares Out | 45.35M |
| EPS (ttm) | -10.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,708,666 |
| Open | 31.89 |
| Previous Close | 31.96 |
| Day's Range | 31.16 - 34.37 |
| 52-Week Range | 12.24 - 34.37 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 39.55 (+18.84%) |
| Earnings Date | May 14, 2026 |
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric co... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MPLT stock is "Strong Buy." The 12-month stock price target is $39.55, which is an increase of 18.84% from the latest price.
News
MapLight Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of MapLight Therapeutics (MPLT) with a Strong Buy rating and $46 price target Cobenfy marks the first major mechanistic innovation in schizophrenia treatment in over t...
MapLight Therapeutics Announces Changes to Board of Directors
SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
MapLight Therapeutics price target lowered to $40 from $43 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on MapLight Therapeutics (MPLT) to $40 from $43 and keeps a Buy rating on the shares. MapLight’s ML-004 Phase 2 IRIS results were mixed…
MapLight Therapeutics Transcript: Study result
ML-004 did not improve social communication in ASD but showed robust, clinically meaningful reductions in irritability among adolescents with moderate to severe symptoms, with effect sizes exceeding current therapies and a favorable safety profile. It was well-tolerated, with no severe adverse events and minimal weight gain or sedation.
MapLight Therapeutics Press release: Study result
MapLight Therapeutics issued a press release on June 22, 2026, disclosing material business information to investors.
MapLight Therapeutics Slides: Study result
MapLight Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
MapLight Therapeutics announces IRIS trial misses primary endpoint
MapLight Therapeutics (MPLT) announced topline results from IRIS, a Phase 2 study of ML-004 in autism spectrum disorder, or ASD. The study randomized 161 participants with prespecified analyses planne...
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering ...
MapLight Therapeutics price target raised to $36 from $28 at Stifel
Stifel raised the firm’s price target on MapLight Therapeutics (MPLT) to $36 from $28 and keeps a Buy rating on the shares following the firm’s recent meetings with CEO Chris…
MapLight Therapeutics initiated with a Buy at UBS
UBS analyst Ashwani Verma initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $48 price target MapLight has a “major near-term catalyst” due in mid-August, says the analyst,…
Craig-Hallum bullish on MapLight Therapeutics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $43 price target The firm views MapLight as a differentiated muscarinic setup where the ke...
MapLight Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Adam Vogel initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $43 price target
MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)
“We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials,” said Chris Kroeger, co-Founder and CEO of…
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004's Phase 2 IRIS trial in autism spec...
MapLight Therapeutics Earnings release: Q1 2026
MapLight Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
MapLight Therapeutics Quarterly report: Q1 2026
MapLight Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
MapLight Therapeutics initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of MapLight Therapeutics (MPLT) with an Outperform rating and $45 price target
MapLight Therapeutics management to meet with Needham
Meeting to be held on May 19 in New York hosted by Needham.
MapLight Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor con...
MapLight Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $45 price target MapLight is a clinical-stage biopharmaceutical company focused on i...
MapLight Therapeutics completes enrollment in ZEPHYR trial
MapLight Therapeutics (MPLT) announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The company also announced completion of the final...
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering f...
MapLight Therapeutics Proxy statement: Proxy filing
MapLight Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MapLight Therapeutics Proxy statement: Proxy filing
MapLight Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MapLight Therapeutics initiated with a Buy at Needham
Needham initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $37 price target The firm believes the muscarinic class is likely to be “disruptive,” with application across multiple…